UCB is listed on the APICS list of global pharmaceutical companies
Public source
Publisher name
Public post
Les diamants sont éternels, C’est du moins ce que promettait James Bond. Les souvenirs et les regrets aussi, aurait peut-être répondu Jacques Prévert. Dans les grandes e…
Company
UCB
We’re #TeamUCB, a global biopharmaceutical company. 💙 Inspired by patients 🔬 Driven by science
- Industry
- Pharmaceutical Manufacturing
- Location
- Brussels, BE
- Company size
- 10,001+ employees
About UCB
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
See moreLatest activity
Latest activity from UCB
11 signals
Presence & Recognition
UCB participated in the Nee Approaches to Allosteric Modulators session at the EFMC - European Federation for Medicinal Chemistry and Chemical Biology International Symposium on Medicinal Chemistry.
Presence & Recognition
UCB participated in the CCBF Ambassade de France au Brésil in São Paulo, Brazil, and hosted a catalog of the Centre de formation Saint-Michel.
Presence & Recognition
UCB contributed to the European Epilepsy Congress at EEC2026 by contributing to conversations on the evolving management of epilepsy and developmental and epileptic encephalopathies.
Discover more
Similar signals
Similar public activity from other companies.
Strategy & Corporate Development
Servier
Servier completed the acquisition of Edgewise Therapeutics’ Muscular Dystrophy Business to strengthen its commitment to rare neurological disorders and advance innovation for patients with Duchenne and Becker muscular dystrophies.
Strategy & Corporate Development
Takeda
Takeda observed that multinationals are paying billions for assets designed by scientists who trained in the US or Europe, worked there for a decade, and went home.
Strategy & Corporate Development
Servier Pharmaceuticals
Servier Pharmaceuticals expanded its rare neurology portfolio through the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business.
Strategy & Corporate Development
Zentiva France
Zentiva France established its 5 core values as the foundation for its identity and transformation.
Strategy & Corporate Development
GSK